Galectin jumps after positive safety update on liver disease therapy

Galectin Therapeutics

14/04/2022 18:52

** Drug developer's shares  GALT.O  jump 10% to $1.74 - set
for third straight session of gains 
    ** Galectin Therapeutics says an independent data and safety
monitoring panel concluded that its mid-to-late stage study
testing its lead drug candidate belapectin can carry on as
planned without changes  urn:newsml:reuters.com:*:nGNX5BV5Q0
    ** Says the panel's objective was to review the tolerance
and safety profile of belapectin, which is being studied in
patients with liver cirrhosis or scarring caused by
non-alcoholic steatohepatitis (NASH)
    ** Stock had fallen 23.7% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))